Share on StockTwits

BioCryst Pharmaceuticals (NASDAQ:BCRX) will be posting its Q214 quarterly earnings results on Tuesday, August 5th. Analysts expect BioCryst Pharmaceuticals to post earnings of ($0.19) per share and revenue of $2.32 million for the quarter.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.17) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.17). The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $3.34 million. During the same quarter last year, the company posted ($0.09) earnings per share. BioCryst Pharmaceuticals’s revenue was down 2.8% compared to the same quarter last year. On average, analysts expect BioCryst Pharmaceuticals to post $-0.75 EPS for the current fiscal year and $-0.41 EPS for the next fiscal year.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 12.54 on Monday. BioCryst Pharmaceuticals has a 1-year low of $4.55 and a 1-year high of $13.33. The stock’s 50-day moving average is $11.98 and its 200-day moving average is $10.54. The company’s market cap is $753.2 million.

A number of research firms have recently commented on BCRX. Analysts at Wells Fargo & Co. upgraded shares of BioCryst Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, June 23rd. They now have a $17.00 price target on the stock, down previously from $19.00. On a related note, analysts at HC Wainwright raised their price target on shares of BioCryst Pharmaceuticals from $21.00 to $24.00 in a research note on Friday, May 30th. They now have a “buy” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of BioCryst Pharmaceuticals from $18.00 to $20.00 in a research note on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $18.13.

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.